[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing QL Biopharmaceutical Co.,Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":130},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,64,86,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100053403","phase-1-a-study-to-investigate-the-effects-of-zovaglutide-zt002-injection-on-qtc-interval-in-healthy-adults-100053403",false,"NCT07697846","A Study to Investigate the Effects of Zovaglutide (ZT002 Injection) on QTc Interval in Healthy Adults","Phase 1, Single-Center, Randomized, Double-Blind, Parallel-Group Placebo-Controlled（Concentration）-QTc（C-QTc）Study to Evaluate the Impact of ZT002 Injection on QTc Interval in Chinese Overweight and Obese Subjects","Inclusion Criteria:\n\n* Ability to understand the trial procedures and possible adverse events, be able and willing to provide a written informed consent;\n* Age between 18 - 45 years (both inclusive) at the time of signing of the informed consent;\n* Male (body weight \\>60.0 kg) or female (body weight \\>55.0 kg). Body mass index (BMI) 24.0 - 35.0 kg\u002Fm²(both inclusive);\n\nExclusion Criteria:\n\n* Known hypersensitivity (asthma, hypersensitivity to GLP-1 receptor agonists or excipients), or known hypersensitivity to ZT002 injection;\n* History of acute or chronic pancreatitis, or pancreatic injury.History of medullary thyroid carcinoma (MTC) or type 2 multiple endocrine neoplasia (MEN2) in personal or family history.\n* Has a history of cardiovascular diseases or risk factors predisposing to torsades de pointes (TdP); has personal or family history of any cardiac conduction abnormalities; has personal or family history of long QT syndrome (LQTS); or has a family history of sudden cardiac death.\n* Those with any type of malignant tumors within 5 years prior to screening (except cured basal cell carcinoma of the skin or carcinoma in situ of the cervix).\n* Medical history of hypoglycemia within 6 months before screening;\n* History of acute or chronic pancreatitis;\n* ECG findings exceeding thresholds at screening or prior to randomization: PR interval \\>220 ms, QRS duration \\>110 ms, heart rate (HR) \\\u003C50 bpm or \\>100 bpm, QTcF ≥450 ms; or presence of any ECG abnormalities deemed clinically significant by the investigator.\n* Glycated hemoglobin (HbA1c) ≥ 6.5% or fasting plasma glucose ≥ 7.0 mmol\u002FL at screening;\n* Aspartate aminotransferase \\> 2 × upper limit of normal (ULN), Alanine aminotransferase \\> 2 × ULN,\n* Alkaline phosphatase total bilirubin \\> 1.5 × ULN;\n* Subjects who have previously undergone gastric bariatric surgery or other weight-loss surgeries, or who plan to receive weight-loss surgery, liposuction, abdominal lipectomy, or other procedures with substantial impacts on body weight during the study.\n* Use of weight-altering medications or therapies within 3 months prior to screening.\n* Administration of any medications known to prolong QT\u002FQTc interval, alter heart rate, or carry risks of torsades de pointes (TdP) within 4 weeks prior to screening\n* Pregnant or lactating women, or subjects with a positive pregnancy test result at screening\u002Fbaseline",true,"ALL","18 Years","45 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This study is designed to investigate the effect of treatment with Zovaglutide (ZT002 Injection) on the corrected cardiac QT interval relative to a placebo control in healthy participants.",[28],"Overweight, Obesity","NOT_YET_RECRUITING","2026-07-06",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":22},"2026-07-18",{"date":37,"type":22},"2027-03-24",{"name":39,"class":40},"Beijing QL Biopharmaceutical Co.,Ltd","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":41},"100635294","phase-1-drug-drug-interaction-study-of-zt002-injection-in-overweight-and-obese-participants-100635294","NCT07550816","Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants","A Drug-drug Interaction Study to Evaluate the Impact of Multiple Subcutaneous Injections of ZT002 on the Pharmacokinetics of Metformin, Warfarin, Rosuvastatin and Digoxin in Overweight and Obese Participants","Inclusion Criteria:\n\n* Age between 18 - 45 years (both inclusive) at the time of signing of the informed consent;\n* Male (body weight \\>60.0 kg) or female (body weight \\>55.0 kg). Body mass index (BMI) 24.0 - 35.0 kg\u002Fm²(both inclusive);\n* Considered to be generally healthy based on physical examination, and the results of vital signs, 12-lead electrocardiogram and clinical laboratory tests (hematology, urinalysis, chemistry, coagulation), as judged by the investigator.\n\nExclusion Criteria:\n\n* Clinically significant diseases detected within 6 months before screening (including but not limited to neurological, psychiatric, cardiovascular, endocrine, gastrointestinal, respiratory, urinary, hematological, immunological diseases), judged by the investigator as possible to influence the study result or introduce safety risk to study drug administration;\n* History of dysphagia or any gastrointestinal tract disease that affects drug absorption;\n* Known hypersensitivity (asthma, hypersensitivity to GLP-1 receptor agonists or excipients), or known hypersensitivity to ZT002 injection;\n* History of inspirational pneumonia within 5 years before screening;\n* Medical history of hypoglycemia within 6 months before screening;\n* History of acute or chronic pancreatitis;\n* Cholelithiasis ≤ 1 cm, or history of cholecystitis or other symptomatic gallbladder disease, with the exception of cholecystectomy \\> 6 months prior to screening;\n* History or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2;\n* Glycated hemoglobin (HbA1c) ≥ 6.5% or fasting plasma glucose ≥ 7.0 mmol\u002FL at screening;\n* Aspartate aminotransferase ≥ 2 × upper limit of normal (ULN), Alanine aminotransferase ≥ 2 × ULN,\n* Alkaline phosphatase total bilirubin ≥ 1.5 × ULN;\n* Calcitonin above ULN at screening;\n* Thyroid stimulating hormone (TSH) \\\u003C 0.4 or \\>6.0 mIU\u002FL;\n* Use of hypoglycemic drugs (e.g. insulin, insulin secretagogues, thiazolidinedione, sodium-dependent glucose transporters 2 inhibitors \\[SGLT2i\\], dipeptidyl peptidase 4 inhibitor \\[DPP-4i\\], glucagon-like peptide-1 receptor agonist \\[GLP-1RA\\], metformin, α-glucosidase inhibitor) within 3 months before screening;\n* Use of prescription drugs, over-the-counter drugs, dietary supplements, vitamins, or herbal medicines (excluding topical eye\u002Fnose drops and external use on the skin without systemic exposure risk) within 2 weeks before screening.\n\nExclusion criteria only applicable to Cohort 1:\n\n* History that increases risk of bleeding, e.g. aneurysm, aortic dissection, cerebral vascular malformation, acute gastritis, gastric or duodenal ulcer; hemorrhoid bleeding within 1 month prior to screening;\n* Hypersensitivity to metformin or warfarin;\n* Prothrombin time (PT), international normalized ratio (INR) or activated partial thromboplastin time (APTT) above ULN and judged as clinically significant by investigator;\n* Platelet \\\u003C 100x109\u002FL;\n* Ventricular rate \\\u003C 50 or \\> 100 bpm, second or third degree of atrioventricular block, left bundle branch block, complete right bundle branch block, or QT interval corrected by Fridericia's formula (QTcF) \\> 450 ms, or other abnormal electrocardiogram of clinical significance.\n\nExclusion criteria only applicable to Cohort 2:\n\n* History of unexplained myalgia or myasthenia, or diagnosed with rhabdomyolysis;\n* Hypersensitivity to rosuvastatin or digoxin;\n* Unexplained creatine kinase above ULN;\n* Serum potassium out of reference range;\n* Ventricular rate \\\u003C 55 or \\> 100 bpm, atrial fibrillation, atrioventricular block of any degree, preexcitation syndrome, left bundle branch block, complete right bundle branch block, or QT interval corrected by Fridericia's formula (QTcF) \\> 450 ms, or other abnormal electrocardiogram of clinical significance.",{"count":50,"type":22},60,[25],"ZT002 is an ultralong-acting glucagon-like peptide-1. This open-label, fixed sequence, two-period crossover drug-drug interaction study is designed to evaluate the impact of ZT002 on the PK of metformin, warfarin, rosuvastatin and digoxin. The study will include obese and overweight but otherwise healthy participants aged 18 - 45.\n\nThe study consists of two cohorts. Each participant can only join one of the cohorts.\n\nCohort 1 evaluates the impact of ZT002 on the PK of metformin at steady state and on the PK of a single dose of warfarin. Participants are screened within 2 weeks before study drug administration. In the first period, metformin is given twice daily for 3.5 days and warfarin is given as a single dose without ZT002. In the second period, metformin and warfarin are given, following the same dose and regimen as in the first period, concomitantly with ZT002, which reaches steady state by up-titration. The participants will be followed up for 6 weeks after the last dose of ZT002.\n\nCohort 2 evaluates the impact of ZT002 on the PK of single doses of rosuvastatin and digoxin. Participants are screened within 2 weeks before study drug administration. In the first period, rosuvastatin and digoxin are given as single doses without ZT002. In the second period, rosuvastatin and digoxin are given, following the same dose and regimen as in the first period, concomitantly with ZT002, which reaches steady state by up-titration. The participants will be followed up for 6 weeks after the last dose of ZT002.",[54],"Overweight,Obesity","RECRUITING","2026-06-18",{"date":58,"type":33},"2026-06-22",{"date":60,"type":33},"2026-05-27",{"date":62,"type":22},"2027-03-26",{"name":39,"class":40},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":23,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},"100627009","phase-1-a-study-of-zovaglutide-zt002-injection-in-participants-with-impaired-kidney-function-and-healthy-participants-100627009","NCT07443059","A Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy Participants","A Phase I Clinical Study to Evaluate the Pharmacokinetic Characteristics and Safety of Single-dose of Zovaglutide (ZT002 Injection) in Participants With Different Degrees of Renal Insufficiency and Matched Participants With Normal Renal Function","Inclusion Criteria:\n\n1. Ability to understand the trial procedures and possible adverse events, be able and willing to provide a written informed consent;\n2. Male or female, age between 18 - 75 years (both inclusive) at the time of signing of the informed consent.\n3. Body mass index (BMI) 19.0 - 32.0 kg\u002Fm²(both inclusive). Body weight ≥50 kg for male participants and ≥45 kg for female participants.\n4. Diagnosed as stable, chronic renal disease for at least 3 months.\n5. Renal function, assessed by estimated glomerular filtration rate at screening (eGFR):\n\n   Normal renal function: 90-129 mL\u002Fmin (inclusive); Mild impairment: 60-89 mL\u002Fmin (inclusive); Moderate impairment: 30-59 mL\u002Fmin (inclusive); Severe impairment: 15-29 mL\u002Fmin (inclusive);\n6. Stable renal function, assessed by two eGFR during screening.\n\nExclusion Criteria:\n\n* All participants will not be included in this study if they meet any of the following criteria:\n\n  1. History of acute or chronic pancreatitis, or pancreatic injury.\n  2. History of medullary thyroid carcinoma (MTC) or type 2 multiple endocrine neoplasia (MEN2) in personal or family history.\n  3. History of depression\u002Fanxiety disorder, or prior diagnosis of moderate-to-severe anxiety\u002Fdepressive state, or history of severe psychiatric disorders;\n  4. Those with any type of treated or untreated malignancy (whether cured or not) within 5 years before screening or during the baseline period (except basal cell carcinoma of the skin)\n  5. Those with any type of malignant tumors within 5 years prior to screening (except cured basal cell carcinoma of the skin or carcinoma in situ of the cervix).\n\n     Participants in the renal insufficiency group will not be included in this study if they meet any of the following criteria:\n  6. Those with obstructive uropathy (e.g., urinary tract obstruction due to calculi or space-occupying lesions) or renal impairment caused by other etiologies unrelated to intrinsic renal dysfunction (e.g., renal tumors) and\u002For renal diseases (e.g., renal artery stenosis, nephrotoxic drugs, severe infections, hypovolemia, heart failure, etc.), and deemed by the investigator as unsuitable for participation in this clinical trial.\n  7. Those with systolic blood pressure exceeding 160 mmHg or diastolic blood pressure exceeding 100 mmHg in the screening period;\n  8. Those who have received any medications known to alter renal tubular creatinine secretion (e.g., cimetidine, trimethoprim, or cibenzoline, or salicylates excluding topical formulations), competitive inhibitors of renal tubular secretion (e.g., probenecid), or nephrotoxic drugs (e.g., non-steroidal anti-inflammatory drugs, polymyxins, vancomycin) within 14 days prior to screening or 5 half-lives (whichever is longer).\n\n     Participants in the normal renal function group will not be included in this study if they meet any of the following criteria:\n  9. Those who have suffered from diseases of other systems, such as the cardiovascular, respiratory, digestive, endocrine, hematologic, or neuropsychiatric systems, within 1 year prior to screening, and are considered by the investigator to be unsuitable for participation in this study.\n  10. Those with systolic blood pressure exceeding 90-140 mmHg (including both end values) or diastolic blood pressure exceeding 50-90 mmHg (including both end values)\n  11. Use of any medication, including prescription drugs, over-the-counter medication, Chinese herbal medicines, and dietary supplements (e.g., vitamins and minerals that may affect study outcomes) within 14 days or 5 half-lives (whichever is longer) prior to screening;","75 Years",{"count":21,"type":22},[25],"This study is a single-dose, open-label, parallel design phase I clinical study to evaluate the PK characteristics and safety of single subcutaneous injection of ZT002 Injection in participants with different degrees of renal insufficiency and matched participants with normal renal function.",[76],"Overweight , Obesity","2026-04-15",{"date":79,"type":33},"2026-04-20",{"date":81,"type":33},"2026-04-13",{"date":83,"type":22},"2027-03-19",{"name":39,"class":40},3,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":41},"100607126","phase-1-study-to-evaluate-the-safety-tolerability-and-pharmacokinetics-of-zt003-injection-following-single-and-multiple-subcutaneous-administration-in-healthy-volunteersoverweight-or-obese-volunteers-100607126","NCT07184502","Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZT003 Injection Following Single and Multiple Subcutaneous Administration in Healthy Volunteers\u002FOverweight or Obese Volunteers","A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZT003 Injection in Healthy Volunteers and Overweight or Obese Volunteers","Inclusion Criteria:\n\n1. Healthy male and female participants, aged 18 to 65 years at the time of screening.\n2. Body weight \\>50 kg to \\\u003C130 kg, and BMI between 22.0 and 45.0 kg\u002Fm square.\n3. Medically healthy, with no clinically significant abnormalities in medical history, physical examination, vital signs, ECG, or clinical laboratory assessments, as judged by the Investigator.\n4. Females of childbearing potential must use highly effective contraception and have a negative pregnancy test at screening and Day -1.\n5. Male participants must agree to use acceptable contraception from screening through at least 90 days after the last dose.\n6. Able to understand and comply with study procedures and provide written informed consent.\n7. Thyroid function tests within normal range as specified by the testing laboratory, unless deemed not clinically significant by the PI or designee.\n\nExclusion Criteria:\n\n1. History or presence of any clinically significant disease or disorder that may put the participant at risk or interfere with study assessments.\n2. Positive test for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), or HIV antibody at screening.\n3. History of drug or alcohol abuse within 12 months prior to screening.\n4. Use of prescription drugs, over-the-counter medications, herbal products, or supplements within 14 days (or 5 half-lives) prior to first dose unless deemed acceptable by the Investigator.\n5. Participation in another clinical study with an investigational product within 30 days or 5 half-lives of the investigational product before dosing.\n6. Any history of significant allergy or hypersensitivity to any component of the investigational medicinal product (IMP).\n7. Clinically significant ECG abnormalities, including QTc \\>450 ms (males) or \\>470 ms (females) at screening.\n8. Abnormal clinical laboratory results at screening considered clinically significant by the Investigator.\n9. History of bleeding disorders or current use of anticoagulant therapy.\n10. Pregnant or lactating females, or females planning to become pregnant during the study period.","65 Years",{"count":95,"type":22},76,[25],"This is a Phase 1, randomized, double-blind, placebo-controlled, single-center study designed to evaluate the safety, tolerability, and pharmacokinetics of ZT003 following subcutaneous administration in healthy adult participants. The study includes both single ascending dose (SAD) and multiple ascending dose (MAD) parts.",[99],"Healthy","2026-01-28",{"date":102,"type":33},"2026-01-30",{"date":104,"type":33},"2025-10-16",{"date":106,"type":22},"2026-10-10",{"name":39,"class":40},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":71,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},"100610633","phase-3-a-study-of-zovaglutide-in-subjects-with-overweight-or-obesity-horizon-1-100610633","NCT07230119","A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Zovaglutide in Adults With Overweight or Obesity.","Inclusion Criteria:\n\n* 1\\. Male or female subjects aged≥18years and≤75 years at the time of signing the ICF.\n* 2.At screening and prior to randomization, BMI must meet one of the following criteria:\n\n  1. BMI≥28kg\u002Fm²regardless of comorbidities；\n  2. BM≤24 kg\u002Fm² and\\\u003C28 kg\u002Fm², with at least one of the following comorbidities: prediabetes, hypertension, dyslipidemia, fatty liver disease, obstructive sleep apnea syndrome due to overweight, or weight-bearing joint pain.\n* 3.Weight change due to diet and exercise alone within 3 months prior to screening and randomization did not exceed 5%.\n\nExclusion Criteria:\n\n* 1.Previously diagnosed obesity caused by monogenic mutations, other diseases, or medications.\n* 2.Previous diagnosis of diabetes; or HbA1c ≥ 6.5% or fasting blood glucose ≥ 7.0 mmol\u002FL at screening.\n* 3.Used of medicines or treatments that affect weight within 3 months prior to screening.\n* 4.History of acute or chronic pancreatitis, or pancreatic injury.\n* 5.History of medullary thyroid carcinoma (MTC) or type 2 multiple endocrine neoplasia (MEN2) in personal or family history.\n* 6.History of depression\u002Fanxiety disorder, or prior diagnosis of moderate-to-severe anxiety\u002Fdepressive state, or history of severe psychiatric disorders;\n* 7\\. PHQ-9 scale score is ≥ 15 at screening;\n* 8\\. Screening C-SSRS questionnaire suicide ideation response of \"Category 4 or 5,\" or any \"yes\" response to suicidal behavior questions.",{"count":116,"type":22},744,[118],"PHASE3","This study will evaluate the percentage change in body weight from baseline and proportion of subjects achieving ≥ 5% weight loss from baseline after 52 weeks of treatment with Zovaglutide in subjects with overweight\u002Fobesity.",[76],"2025-12-17",{"date":123,"type":33},"2025-12-23",{"date":125,"type":22},"2026-03-08",{"date":127,"type":22},"2027-06-26",{"name":39,"class":40},25,""]